Table 1.

Cytotoxicity of RTS-V5 and ricolinostat against selected leukemia and multiple myeloma cell lines as well as patient-derived BCP-ALL cells.

Cell line	Characteristic	RTS-V5 IC50[μM]	Ricolinostat IC50[μM]
HL60	AMLa	1.55 ± 0.02	2.36 ± 0.07
SEM	BCP-ALLb	0.89 ± 0.01	1.61 ± 0.02
SUP-B15	BCP-ALLb	1.77 ± 0.02	1.92 ± 0.07
KCL-22	CMLc	3.14 ± 0.03	3.75 ± 0.09
SUP-B15r	BCP-ALLb,d	1.83 ± 0.03	3.54 ± 0.02
KCL-22r	CMLc,d	2.58 ± 0.04	3.38 ± 0.03
RPMI-8226	MMe	1.75 ± 0.32	1.97 ± 0.12
U266	MMe	2.04 ± 0.37	3.52 ± 0.38
Patient 1	BCP-ALLb	2.06 ± 0.16	0.29 ± 0.01
Patient 2	BCP-ALLb	1.84 ± 0.07	0.58 ± 0.04
Patient 3	BCP-ALLb	5.23 ± 0.13	4.45 ± 0.14
Patient 4	BCP-ALLb	1.51 ± 0.05	0.54 ± 0.01

^aAcute myeloid leukemia.

^bB-cell precursor acute lymphoblastic leukemia.

^cChronic myeloid leukemia.

^dImatinib resistant.

^eMultiple myeloma.